Author: Ben Rogers
When IBD Affects Your Breathing: A Hidden Risk You Should Know
New research reveals people with IBD face nearly 50% higher risk of developing interstitial lung disease. Here’s what this means for your health and how to discuss it with your medical team.
Obefazimod Shows Promise: A New Hope for Crohn’s Treatment
Abivax’s obefazimod shows promising Phase 2b results for moderate to severe Crohn’s disease, offering hope through a novel treatment mechanism. This oral medication could provide new options for patients who haven’t found success with current therapies.
Life After Colectomy: New Hope for Crohn’s Disease of the Pouch
New research shows that two biologic medications, ustekinumab and vedolizumab, offer effective treatment options for people who develop Crohn’s disease of the pouch after ulcerative colitis surgery. This gives hope to patients facing this challenging post-surgical complication.
AZD7798 for Crohn’s Disease: What AstraZeneca’s CALLISTO Trial Is Testing
AstraZeneca’s experimental treatment AZD7798 takes a precision approach to Crohn’s disease, targeting specific immune cells that cause gut inflammation rather than suppressing the entire immune system. This targeted therapy could offer new hope for patients seeking effective treatment with fewer side effects.
Hope on the Horizon: New Crohn’s Trial May Change Everything for Kids
AbbVie announces a promising new clinical trial studying Upadacitinib for children and teens with moderate to severe Crohn’s disease. This research could expand treatment options for our youngest IBD warriors who have historically had fewer therapeutic choices than adults.
Risankizumab vs Ustekinumab for Crohn’s: Phase 3 Head-to-Head Results
New Phase 3 study results show risankizumab offering hope for Crohn’s patients who haven’t responded to anti-TNF therapies. The treatment’s convenient home delivery system is also improving patient confidence and quality of life.
New Crohn’s Treatment Shows Promise for True Healing
New clinical trial results show risankizumab achieving 52% remission rates and actual tissue healing in Crohn’s patients. This breakthrough suggests we may be moving beyond symptom management toward true intestinal repair.
The Hidden Cost of Waiting: Why IBD Diagnosis Delays Matter
New research reveals that delays in IBD diagnosis lead to worse health outcomes, including increased need for surgery and complications. Understanding this connection can help current patients advocate for faster diagnosis and appropriate care.
New Hope: Revolutionary Crohn’s Therapy Enters Clinical Trials
Researchers at the Hudson Institute have developed a groundbreaking therapy for perianal Crohn’s disease using extracellular vesicles that could sidestep the cost and accessibility challenges of traditional stem cell treatments. This innovative approach has entered clinical trials, offering new hope for patients with one of IBD’s most challenging manifestations.
New Hope for Perianal Crohn’s: Upadacitinib Shows Promise
New research shows upadacitinib may offer hope for perianal fistulizing Crohn’s disease, with nearly half of patients achieving clinical remission after 24 weeks. This breakthrough represents meaningful progress for those who haven’t found relief with traditional treatments.
